The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 01, 2015

Filed:

Dec. 18, 2013
Applicants:

Paul Allegretti, Fort Collins, CO (US);

Seok-ki Choi, Ann Arbor, MI (US);

Paul R. Fatheree, San Francisco, CA (US);

Roland Gendron, San Francisco, CA (US);

Ryan Hudson, San Jose, CA (US);

Keith Jendza, Boston, MA (US);

Robert Murray Mckinnell, Millbrae, CA (US);

Darren Mcmurtrie, Foster City, CA (US);

Brooke Olson, Williamstown, MA (US);

Inventors:

Paul Allegretti, Fort Collins, CO (US);

Seok-Ki Choi, Ann Arbor, MI (US);

Paul R. Fatheree, San Francisco, CA (US);

Roland Gendron, San Francisco, CA (US);

Ryan Hudson, San Jose, CA (US);

Keith Jendza, Boston, MA (US);

Robert Murray McKinnell, Millbrae, CA (US);

Darren McMurtrie, Foster City, CA (US);

Brooke Olson, Williamstown, MA (US);

Assignee:

Theravance Biopharma R&D IP, LLC, South San Francisco, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 235/08 (2006.01); A61K 31/4184 (2006.01); C07D 401/12 (2006.01); C07D 403/10 (2006.01); C07D 403/12 (2006.01); C07D 405/12 (2006.01); A61K 31/4439 (2006.01); A61K 31/5377 (2006.01); A61K 45/06 (2006.01); C07D 405/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4184 (2013.01); A61K 31/4439 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07D 235/08 (2013.01); C07D 401/12 (2013.01); C07D 403/10 (2013.01); C07D 403/12 (2013.01); C07D 405/10 (2013.01); C07D 405/12 (2013.01);
Abstract

The invention is directed to compounds having the formula: wherein: Ar, r, n, X, Rand Rare as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have ATreceptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.


Find Patent Forward Citations

Loading…